National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Patiromer (Veltassa®)

Patiromer (Veltassa®) is indicated for the treatment of hyperkalaemia in adults.

NCPE Assessment Process Complete
Rapid review received 11/10/2017
Rapid review completed 17/11/2017
Rapid Review outcome Full pharmacoeconomic assessment
Full pharmacoeconomic assessment commissioned by HSE 20/11/2017
Pre-submission consultation with Applicant 16/01/2018
Submission received from Applicant 13/04/2018
Preliminary review sent to Applicant 15/10/2018
NCPE assessment re-commenced 13/11/2018
Factual accuracy sent to Applicant 21/01/2019
NCPE assessment re-commenced 04/02/2019
NCPE assessment completed 13/02/2019
NCPE assessment outcome The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.


Re-submission of HTA

NCPE Assessment Process Ongoing
Re-submission of HTA commissioned by the HSE 30/06/2020
Pre-submission consultation with Applicant 23/11/2020
Current status Awaiting HTA submission from Applicant